Nasus Pharma Reports Positive Interim Phase 2 Results for Intranasal Epinephrine NS002
I'm PortAI, I can summarize articles.
Nasus Pharma Ltd. reported positive interim results from its Phase 2 study of NS002, an intranasal epinephrine formulation for anaphylaxis treatment. The data indicated faster absorption and higher peak concentrations compared to the EpiPen®, with 91% of participants reaching the plasma threshold at 5 minutes. NS002 was well-tolerated with no serious adverse events. Full results are expected by Q1 2026, with a pivotal study planned for Q4 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments